BridgeMD
New treatment option for Hearing Loss
Official title Fall Risk Assessment and Speech Intelligibility Enhancement Using In-ear Device
ClinicalTrials.gov ID: NCT05365646
What this study is testing
- What it's testing
- The purpose of this study is to develop and validate methods to use hearing aids equipped with embedded sensors and artificial intelligence to assist in the assessment of fall risk and in the implementation of interventions aimed at reducing the risk of falling, as well as to improve speech intelligibility in quiet and in background noise, track physical activity, and social engagement. The investigators hope is that the knowledge that is generated through this study will ultimately translate to the clinical setting and will help reduce the likelihood that individuals experience a fall, and improve the quality of hearing in individuals who wear hearing aids.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 55 and older. Healthy volunteers may be eligible.
You may be able to join if
- Age 55 years or older
- Bilateral hearing aid user
- Able to consent in English
- Having access to a phone capable of running the mobile app required for the study
- Screen for fall risk ("Yes" to any question: Feels unsteady when standing or walking? Worries about falling? Has fallen in past year? If the...
You likely can't join if
- People with mobility restrictions (e.g., wheelchair bound) that would prevent the performance of the functional assessments.
- People with severe movement (e.g., Advanced Parkinson's disease) or cognitive (e.g., advanced dementia) disorders that would prevent the individual...
- Inability to understand, consent, and complete requirements including verbal instructions and non-ambulatory/wheelchair-dependent.
See the full eligibility criteria
- Age 55 years or older
- Bilateral hearing aid user
- Able to consent in English
- Having access to a phone capable of running the mobile app required for the study
- Screen for fall risk ("Yes" to any question: Feels unsteady when standing or walking? Worries about falling? Has fallen in past year? If the participant has fallen: how many times? were they injured/hurt?)
- Ambulatory without need for a wheelchair
- People with mobility restrictions (e.g., wheelchair bound) that would prevent the performance of the functional assessments.
- People with severe movement (e.g., Advanced Parkinson's disease) or cognitive (e.g., advanced dementia) disorders that would prevent the individual from either performing the functional assessments, or would lead to...
- Inability to understand, consent, and complete requirements including verbal instructions and non-ambulatory/wheelchair-dependent.
The study team makes the final eligibility decision.
Where it's taking place
- Palo Alto, California, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 55 years and older. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Palo Alto, California, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.